How much funding can be received?

Receive strategic guidance from an international Steering Committee of investors, healthcare executives, and advisors in order to position your company for fundraising periods and accelerate technology commercialization.

grant_single_labels|projects

grant_single|admissibleProjectsExample

$70,000

Start a new fitness studio offering specialized wellness programs

$90,000

Create an online platform for financial literacy among teenagers

$100,000

Develop a new healthcare app to monitor patient vitals in real time

$120,000

Create a sustainable fashion brand using eco-friendly materials

$150,000

Launch a cooperative grocery store focused on local and organic products

$60,000

Establish a new non-profit organization focused on mental health awareness campaigns

grant_single_labels|admissibility

Eligibility for participation in OBIO’s CAAP® program requires meeting specific criteria related to company profile and funding stage.

The company must be in the health sciences sector.
The company should be starting to raise Series A financing in the Q4 2023 to 2024 timeframe.

grant_eligibility_criteria|who_can_apply

Participants in the OBIO® Capital Access Advisory Program (CAAP®) are health science companies embarking on raising Series A financing and aiming for high-value investment opportunities.

grant_eligibility_criteria|eligible_expenses

The CAAP® program supports activities centered around strategic business growth and investment attraction in the health sciences sector. Eligible activities are designed to enhance company readiness and success in securing Series A financing and strategic partnerships.

Business strategic planning and optimizing return on investment for investors.
Advanced fundraising strategies and comprehensive financial modeling.
Closing an investment round to secure funding.

grant_single_labels|criteria

There are evaluation and selection criteria for the OBIO CAAP® grant program:

Demonstrated potential for technology commercialization and scalability
Evidence of business strategic planning and market feasibility
Ability to articulate advanced fundraising strategies and financial modeling
Clear plan for closing an investment round

grant_single_labels|register

Here are the steps to submit an application for the OBIO® Capital Access Advisory Program (CAAP®):

Step 1: Check Eligibility
- Ensure your company is a health science company looking to raise Series A financing in Q4 2023 to 2024.
Step 2: Program Application
- Visit the OBIO® official website to find the CAAP® application form or contact the provided emails for access.
- Fill in the application form with company details, business strategy, and fundraising plans.
Step 3: Submit Application
- Email the completed application form to the contacts provided (e.g., christinayeh@obio.ca or jacklee@obio.ca).
- Ensure submission before any specified deadline.
Step 4: Review and Confirmation
- Wait for confirmation of receipt from OBIO®.
- They may request additional information or documents as needed.

grant_single_labels|otherInfo

Here are additional relevant details for this program:

The OBIO Investment Summit provides an opportunity for direct interaction with global health sciences investors and strategic partners.
Since 2018, over $1.6 billion has been raised by companies participating in the Summit, highlighting a successful track record.
Over 200 companies have previously presented at the OBIO Investment Summit, offering a platform for visibility and networking.
The program offers access to a network of advisors specializing in technology commercialization, business development, and fundraising.
Strategic guidance is provided by an international Steering Committee comprising investors, healthcare executives, and business experts.

grant_single_labels|documents

Capital Access Advisory Program — Building Companies

Apply to this program

Accelerate Your Health Science Company's Growth with CAAP®

The OBIO® Capital Access Advisory Program (CAAP®) offers a structured 9-month initiative aimed at health science companies seeking to secure Series A financing and forge strategic partnerships. By providing focused strategic planning, advanced fundraising strategies, and preparation for investment rounds, CAAP® positions these companies for success in the competitive biotech and health sciences sector.

Dive Deep into the Dynamics of CAAP® and Its Lasting Influence

The Capital Access Advisory Program (CAAP®), orchestrated by the Ontario Bioscience Innovation Organization (OBIO), stands as a pivotal intervention in the landscape of Canadian health sciences. Tailored specifically for ambitious companies on the brink of a Series A financing breakthrough, CAAP® facilitates a transformation phase where burgeoning startups can thrive into fully-fledged growth enterprises. Over its 9-month duration, CAAP® offers an intensive curriculum designed to endow participant companies with the agility and foresight needed to stand out to investors.

Funded by both the Government of Canada and the region of Ontario, CAAP® is a testament to the commitment toward fostering innovation and excellence in the health sciences sector – an arena known for its competitive edge and transformational potential. Within this framework, enterprises are ushered into a realm of strategic growth opportunities, equipped with tools to enhance their business plans, refine investor pitches, and access a rich network of global investors.

Central to the CAAP® experience is the encapsulation of three core competencies: business strategic planning aimed at enhancing investor ROI, advancing fundraising stratagems coupled with rigorous financial modeling, and mastering the nuances of concluding investment rounds with efficacy. Participants gain unparalleled access to an international Steering Committee composed of investors, healthcare executives, and business savants. This coalition works tirelessly to furnish participant companies with personalized guidance and strategic oversight, ensuring that every presentation and negotiation is hinged on a position of strength and clarity.

Investor readiness is a hallmark of the CAAP® process, driven by targeted introductions and access to a rich trove of potential stakeholders within the healthcare sector. To date, the OBIO® Investment Summit, which forms the crescendo of the CAAP® program, has witnessed over 200 companies present to an audience of discerning global health sciences investors. This summit is not just a showcase but a robust platform for solidifying partnerships and securing essential financial backing, which has resulted in over $1.6 billion being raised by participating companies since 2018.

While the current focus is on companies poised to launch into Series A rounds from late 2023 into 2024, CAAP® maintains a legacy of success stories, tracing its impact through previous years and evidencing its capacity to consistently nurture promising ventures into success. By embedding within a cycle of strategic preparation and enhancement, CAAP® graduates depart from the program with a fortified business disposition, ready to conquer the challenges of scaling and innovation within their field.

In conclusion, CAAP® serves as more than just an accelerator. It epitomizes a critical intersection where advanced bioscience ventures gain the infrastructural and intellectual resources needed to leap into their next phase of growth. Through this commitment to excellence and innovation, CAAP® continues to provide unparalleled pathways for the realization of the immense potential residing within Canada's vibrant health sciences sector, thereby transforming both the local and global commercial landscapes.